Fig. 5 | Scientific Reports

Fig. 5

From: Epigenetic drug screening identifies enzyme inhibitors A-196 and TMP-269 as novel regulators of sprouting angiogenesis

Fig. 5The alt text for this image may have been generated using AI.

Pro-angiogenic effects of SUV4-20H1/H2 inhibitor compound A-196. A) Representative confocal microscopy images of DMSO control and A-196 (1 µM) treatment groups in HUVEC fibrin bead assay showing the difference of the EC sprouting between these groups. F-actin is stained using phalloidin-A635 (red), and nuclei with DAPI (cyan). Scale bar, 200 µm. C) Quantitation of sprout number, length and width showing the pro-angiogenic effect of A-196 treatment. Images were analyzed using SproutAngio tool. n = 3–5 beads/group. B) Human angiogenesis protein array result showing the increased levels of angiogenesis related proteins in the A-196 treatment group compared to the control. D-E) The enrichment analysis of differentially expressed genes showing the effects of the A-196 compound treatment at 72 h timepoint for fibroblast HPF-c cells (D) and HUVECs (E) detected by bulk RNA-sequencing. F) qPCR results of chromatin immunoprecipitation, calculated as percentage of input DNA, for H4K20me1, H4K20me2 and H4K20me3 antibodies at the target genes are indicated. n = 3 /group.

Back to article page